Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by MoriaDwarfon Oct 02, 2016 9:04am
105 Views
Post# 25299490

RE:800k doctors in the U.S and 80k in Canada

RE:800k doctors in the U.S and 80k in Canada
Nailbiter1 wrote: I'm not sure what the medical target group is with these blood screens. G.P.(family doctors) or specialists in the fields of mammography, oncology, hematology, proctology, pulmonary... The G.P.'s far outnumber the specialists. this would have a considerable impact on the numbers. I've been looking for that info but can't seem to find it. Because of my abnormal schedule, I can't commit to attending the live video conferences offered by the company CEO. He would be the one to know. Either way, just the fact that interest seems to gaining momentum with investors is a positive sign. An oncologist in Ottawa that I spoke with recently is invested in GEN and has strong conviction that it is a powerful tool in an arsenal of new cancer sciences that will save many lives. When it's backed by the pros, that's good enough for me.


The GPS are usually in charge of prescribing these early detection tests, at least this the case for colonoscopies and prostate PSA tests (and mammographies?). One should not forget either that early detection usually involves retesting the same patients at regular intervals past a certain age or if you are part of an at-risk group. So, for example, the same 10000 clients might be retested twice or thrice in their lifetimes... plus the yearly crop of new clients. It all works like cou,pound interest. The potential is truly huge!

MoriaDwarf
Bullboard Posts